Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
Prasol Chemicals reports Q2 FY27 PAT up 122% YoY to ₹37.9 Cr; H1 FY27 revenue up 37% to ₹846.2 Cr
Prasol Chemicals released its Q2 and H1 FY27 earnings presentation, posting a 38.6% YoY rise in Q2 revenue to ₹412.6 crore and a 122.2% jump in PAT to ₹37.9 crore. For H1 FY27, revenue reached ₹846.2 crore (up 37.1% YoY) with an EBITDA of ₹148.0 crore (up 106.6% YoY) and EBITDA margin expanding 590 bps to 17.5%. The company reaffirmed its full-year FY27 guidance of ₹1,550–1,650 crore in revenue and ₹240–250 crore in EBITDA. Margins benefited in Q1 from geopolitical supply chain impacts boosting average selling prices by ₹25 crore, which normalized in Q2.
high confidence
What changedPrasol Chemicals reported strong operational growth for Q2 FY27 and updated investors on business strategy, capacity expansions, and full-year FY27 guidance.
Why it mattersThe performance shows strong operating leverage, a normalized post-Mahad-shutdown recovery, improved margins through downstream product additions, and debt reduction on the balance sheet.
📅 Short termEarnings reaction should be positive given the sharp YoY expansion in revenue and profits, although management noted higher raw material costs and freight delays in exports.
📈 Long termStructural expansion into secondary and tertiary derivatives (ZDDP, IPH, PPS) alongside backward integration is supporting improved gross margins from 26% in FY24 to 34% in H1 FY27.
⚠ Risk flags
Volatility in raw material prices
Export shipment delays and elevated freight costs tied to Middle East disruptions
Working capital expansion with inventories rising to ₹301.1 crore from ₹153.2 crore
👀 What to Watch
Track progress on ongoing phased capacity expansions and watch whether EBITDA margins sustain in the 14-17% range as raw material pricing and export freight conditions fluctuate.
Prasol Chemicals released the transcript of its maiden earnings call post-listing on September 16, 2026. Management guided for an annual turnover of ₹1,550 to ₹1,600 crore, following ₹1,200+ crore turnover and 21%+ ROCE in the prior year. The company utilized ₹60 crore from IPO proceeds to pay off all targeted debt, making it virtually net debt-free. It has surplus land of 20 acres at Mahad and 10-12 acres at Khopoli to support upcoming product expansions as plants near 70%+ capacity utilization.
high confidence
What changedSubmission of the formal transcript of the Q1 FY27 post-listing analyst earnings call held on September 29, 2026.
Why it mattersProvides investors with direct management guidance, balance sheet status (post-IPO debt reduction of ₹60 crore), and visibility into upcoming expansion phases on owned land.
Expected annual turnover: INR1,550 to INR1,600 croresDebt repaid from IPO proceeds: INR60 croresPrevious year turnover: INR1,200 crores-plusPrevious year ROCE: 21-plus%Q1 FY27 Revenue: ₹433.646 cr
📅 Short termPositive operational clarity following the recent September 2026 IPO listing, supporting sentiment around strong growth guidance.
📈 Long termPrasol's model of plowing back 85-90% of earnings into expansion and maintaining unencumbered adjacent land positions it well for multi-year specialty chemical growth.
⚠ Risk flags
Long gestation timelines for environmental clearances (9 to 12 months) for newer chemistries
Key feedstock dependence on acetone (~40%) and phosphorus (~38-40%)
👀 What to Watch
Track execution of planned capacity expansion breakdown between Khopoli and Mahad, as well as timeline for environmental clearances on new chemistries.
Prasol Chemicals Reports Q1 FY27 Revenue Up 36% to ₹433.6 Cr; Plans ₹300 Cr Capex
Prasol Chemicals filed its Q1 FY27 earnings presentation following its recent IPO listing on September 16, 2026. Total revenue grew 35.5% YoY to ₹433.6 crore, while EBITDA surged 122.4% YoY to ₹90.3 crore, and PAT increased 150.7% to ₹61.0 crore. Operating margins were temporarily boosted by higher average selling prices worth ₹25 crore due to geopolitical supply chain disruptions. The company plans a ₹300 crore capex for expanding existing product lines and guides for FY27 revenue of ₹1,550–1,650 crore.
high confidence
What changedPrasol Chemicals released its first quarterly presentation post-listing, disclosing strong Q1 FY27 performance and formal FY27 operational guidance.
Why it mattersDemonstrates robust top-line growth and turnaround at the Mahad facility, though reported margins benefited from temporary supply-chain-driven price surges.
📅 Short termMarket sentiment should react positively to the strong triple-digit earnings growth, though the management's commentary notes margins will likely normalize in future quarters.
📈 Long termSupported by the turnaround of the Mahad unit, ramp-up in secondary/tertiary derivatives, and ₹300 crore capex into complex specialty chemistries.
⚠ Risk flags
Margin volatility: Q1 gross profit included a temporary ₹25 crore gain from geopolitical supply-chain disruptions that may not recur.
Export logistics risk due to ongoing West Asia conflict affecting shipment schedules.
👀 What to Watch
Track the sustainability of EBITDA margins as management expects the ₹25 crore geopolitical pricing tailwind to normalize in upcoming quarters, alongside execution updates on the ₹300 crore capex.
Prasol Chemicals Q1 PAT Surges 151% YoY to ₹61.02 Cr; Revenue Up 35.7% to ₹433.65 Cr
Prasol Chemicals reported its first financial results post-listing for the quarter ended June 30, 2026, posting a 150.7% YoY increase in Net Profit to ₹610.23 million (₹61.02 crore) compared to ₹243.38 million in Q1 FY25. Revenue from operations increased 35.7% YoY to ₹4,336.46 million (₹433.65 crore) from ₹3,195.60 million. Profit Before Tax climbed 154.9% YoY to ₹835.58 million. The board also noted the retirement of Dr. Chitra Vaidya, Vice-President – R&D, effective September 30, 2026.
high confidence
What changedPrasol Chemicals approved its first post-listing quarterly results (Q1 FY27) and recorded the retirement of its R&D head.
Why it mattersDemonstrates robust top-line growth (35.7% YoY) and significant margin expansion post-IPO, setting the baseline for performance as a newly listed public company.
Revenue from operations (Q1): Rs 4,336.46 millionProfit after tax (Q1): Rs 610.23 millionEPS (Basic and Diluted): Rs 10.52IPO total issue size: Rs 5,000 Million
📅 Short termMarket sentiment should react favorably to the strong YoY jump in quarterly PAT and revenue in its debut post-IPO quarterly reporting.
📈 Long termSustaining quarterly margins above recent annual averages will be key to long-term valuation in the specialty chemicals sector.
⚠ Risk flags
Retirement of senior R&D management personnel
Results for Q4 FY26 (ended March 31, 2026) were neither audited nor subject to limited review
👀 What to Watch
Track the deployment of ₹800 million fresh IPO proceeds and watch how operating margins perform across upcoming quarters following strong Q1 profitability.
📊 Last 7 days — analysed filings by sentiment
positivenegativeneutralwatch
⚠️How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI
⚡ Free FlashFinance Newsletters
AI-powered market intelligence in your inbox — completely free. Pick your topics; max 1 email per topic per day. Unsubscribe anytime.
✅ Everything below is 100% free — no payment, no card, ever.
🎉
You're subscribed!
A welcome email with your topics is on its way. Want it even faster? Join us on Telegram or WhatsApp:
